Skip to main content
SpringerLink
Log in

Romidepsin in the Treatment of T-Cell Lymphoma

Profile Report

  • Adis Profile Report
  • Published:
BioDrugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin’s lymphomas (version 3.2011) [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf [Accessed 2011 Jul 6]

  2. O’Leary HM, Savage KJ. Update on the World Health Organization classification of peripheral T-cell lymphomas. Curr Hematol Malig Rep 2009 Oct; 4 (4): 227–35

    Article  PubMed  Google Scholar 

  3. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2008, National Cancer Institute [online]. Available from URL: http://seer.cancer.gov/csr/1975_2008/results_merged/sect_19_nhl.pdf [Accessed 2011 Jul 6]

  4. Whittaker SJ, Marsken JR, Spittle M, et al. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003 Dec; 149 (6): 1095–107

    Article  PubMed  CAS  Google Scholar 

  5. Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006 May; 42 (8): 1014–30

    Article  PubMed  Google Scholar 

  6. Kimby E. Management of advanced-stage peripheral T-cell lymphomas. Curr Hematol Malig Rep 2007 Oct; 2 (4): 242–8

    Article  PubMed  Google Scholar 

  7. Vose J, Armitage J, Weisenburger D, et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. International T-Cell Lymphoma Project. J Clin Oncol 2008 Sep 1; 26 (25): 4124–30

    Article  PubMed  Google Scholar 

  8. Rizvi MA, Evens AM, Tallman MS, et al. T-cell non-Hodgkin lymphoma. Blood 2006 Feb 15; 107 (4): 1255–64

    Article  PubMed  CAS  Google Scholar 

  9. Kwong YL, Anderson BO, Advani R, et al. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009 Nov; 10 (11): 1093–101

    Article  PubMed  Google Scholar 

  10. Laport GG. Peripheral T-cell lymphoma: autologous hematopoietic cell transplanation as first-line therapy. Curr Opin Oncol 2010 Sep; 22 (5): 409–13

    Article  PubMed  Google Scholar 

  11. Rahman F, Robey RW, Bates SE, et al. Histone deacetylase inhibitors in oncology. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy: principles and practice. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2011: 442–58

    Google Scholar 

  12. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009 Nov 10; 27 (32): 5459–68

    Article  PubMed  CAS  Google Scholar 

  13. Lansigan F, Foss FM. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 2010; 70 (3): 273–86

    Article  PubMed  CAS  Google Scholar 

  14. Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials [published erratum appears in Drugs 2009; 69 (15): 2102]. Drugs 2009; 69 (14): 1911–34

    Article  PubMed  CAS  Google Scholar 

  15. Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res 2009 Jun 15; 15 (12): 3918–26

    Article  PubMed  CAS  Google Scholar 

  16. Celgene Corporation. Istodax® (romidepsin) for injection: US prescribing information [online]. Available from URL: http://www.istodax.com/pdfs/ISTODAX_PackageInsert.pdf [Accessed 2011 Jul 6]

  17. Merck Sharp & Dohme Corp. Zolinza® (vorinostat) capsules: US prescribing information [online]. Available from URL: http://www.merck.com/product/usa/pi_circulars/z/zolinza/zolinza_pi.pdf [Accessed 2011 Jul 6]

  18. Ueda H, Nakajima H, Hori Y, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968.I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 1994 Mar; 47 (3): 301–10

    Article  CAS  Google Scholar 

  19. Furumai R, Matsuyama A, Kobashi N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002 Sep 1; 62 (17): 4916–21

    PubMed  CAS  Google Scholar 

  20. Bradner JE, West N, Grachan ML, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010 Mar; 6 (3): 238–43

    Article  PubMed  CAS  Google Scholar 

  21. Bantscheff M, Hopf C, Savitski MM, et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 2011 Mar; 29 (3): 255–65

    Article  PubMed  CAS  Google Scholar 

  22. Dickinson M, Johnstone RW, Prince HM. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs 2010 Dec; 28Suppl. 1: S3–20

    Article  PubMed  Google Scholar 

  23. Yang LPH. Romidepsin: in the treatment of T-cell lymphoma. Drugs 2011; 71 (11): 1469–80

    Article  PubMed  CAS  Google Scholar 

  24. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009 Nov 10; 27 (32): 5410–7

    Article  PubMed  CAS  Google Scholar 

  25. Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010 Oct 10; 28 (29): 4485–91

    Article  PubMed  CAS  Google Scholar 

  26. Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011 Jun 2; 117 (22): 5827–34

    Article  PubMed  CAS  Google Scholar 

  27. Coiffier B, Pro B, Prince HM, et al. Final results form a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) following prior systemic therapy [abstract no. 114]. 52nd Annual Meeting and Exposition of the American Society of Hematology; 2010 Dec 4–7; Orlando (FL)

Download references

Acknowledgments and Disclosures

The full text article[23] from which this profile report was derived was reviewed by: S.E. Bates, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA; C. Gisselbrecht, Institut d’Hématologie, Hôpital Saint Louis, Paris, France; R.L. Piekarz, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA; T. Robak, Department of Hematology, Medical University of Lodz, Lodz, Poland.

The manufacturer of the agent under review was offered an opportunity to comment on the original article[23] during the peer review process. Changes based on any comments received were made by the author on the basis of scientific and editorial merit. The preparation of the original article and this profile report was not supported by any external funding.

Author information

Authors and Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, 0754, New Zealand

    Lily P. H. Yang

Authors
  1. Lily P. H. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lily P. H. Yang.

Additional information

Adapted and reproduced from the original article published in Drugs 2011; 71 (11): 1469–80

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, L.P.H. Romidepsin in the Treatment of T-Cell Lymphoma. BioDrugs 25, 393–395 (2011). https://doi.org/10.2165/11207660-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11207660-000000000-00000

Keywords

Search

Navigation